Results 11 to 20 of about 7,846,955 (114)
Haematologica, 2017 Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no consensus on the optimal graft-versus-host disease prophylaxis.
Annalisa Ruggeri +17 more
doaj +1 more source
Breakdown of thymic tolerance - an etiologic link between acute and chronic graft-versus-host disease [PDF]
, 2014 Allogeneic haematopoietic stem cell transplantation (HSCT) is the standard therapy for many disorders of the haematological system. Its use is limited by the major complication acute graft-versus-host disease (GVHD). Development of acute GVHD predisposes
Dertschnig, Simone
core +1 more source
Haematologica, 2016 Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén +8 more
doaj +1 more source
Chronic graft-versus-host disease – the role of dermatological treatment [PDF]
, 2017 Introduction . The number of allogeneic haematopoietic stem cell transplantations is increasing year by year. The most common long-term complication is chronic graft-versus-host disease, with skin involvement noted in over 90% of cases. Objective . To
Joanna Gruber-Kopczyńska +3 more
core +1 more source
Frontiers in Immunology, 2017 BackgroundGraft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the ...
Aude Burlion +4 more
doaj +1 more source
Korean Journal of Transplantation, 2023 Background : Graft-versus-host disease (GVHD) is a rare, but potentially fatal complication of liver transplantation. One-way human leukocyte antigens (HLA) mismatch has emerged as a risk factor for GVHD.
Seung Hyuk Yim +4 more
doaj +1 more source
Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]
, 2003 Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Kolb, Hans-Jochem +8 more
core +1 more source
, 2013 We present a case of chronic graft-versus-host disease in a 61-year-old woman with a history of B-cell chronic lymphocytic leukemia that was treated with an allogeneic bone marrow transplant from an unrelated donor.
Latkowski, Jo-Ann +8 more
core +1 more source
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study [PDF]
, 2019 Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids.
González Vicent, Marta +109 more
core +3 more sources